Системный обзор и мета-анализ эффективности внутрипузырной терапии при мочепузырном болевом синдроме/интерстициальном цистите
##plugins.themes.bootstrap3.article.main##
Анотація
##plugins.themes.bootstrap3.article.details##
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Автори зберігають авторське право, а також надають журналу право першого опублікування оригінальних наукових статей на умовах ліцензії Creative Commons Attribution 4.0 International License, що дозволяє іншим розповсюджувати роботу з визнанням авторства твору та першої публікації в цьому журналі.
Посилання
Hanno P, Dmochowski R (2009) Status of international consensus on interstitial cystitis/bladder pain syndrome: 2008 snapshot. Neurourol Urodyn 28:274–286. https://doi.org/10.1002/nau.20687
Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, Shackelford DL, Stein P, Parsons CL (1996) A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology 48:817–821. https://doi.org/10.1016/S0090-4295(96)00322-6
Parsons CL, Lilly JD, Stein P (1991) Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145:732–735. https://doi.org/10.1016/S0022-5347(17)38437-9
Parsons CL (1996) Potassium sensitivity test. Tech Urol 2:171–173.
Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pfluger H (2003) Comparative assessment of maximal bladder capacity, 0.9% NaCl vs. 0.2 M KCl, for the diagnosis of interstitial cystitis: a prospective controlled study. J Urol 170:807–809 https://doi.org/10.1097/01.ju.0000081163.46167.82
Daha KL, Riedl CR, Lazar D, Simak R, Pfluger H (2008) Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol 8:1–4. https://doi.org/10.1080/00365590701871518
Madersbacher H, van Ophoven A, van Kerrebroeck PEVA (2013) GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans – a review. Neurourol Urodyn 32:9–18. https://doi.org/10.1002/nau.22256
Von Heyden B, Schmid HP (2000) Intravesical therapy of interstitial cystitis. Urologe A 39:542–544. https://doi.org/10.1007/s001200050406
Rovner E, Propert KJ, Bresinger C, Wein AJ, Foy M, Kirkemo A et al (2000) Treatment used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology 26:940–945. https://doi.org/10.1016/S0090-4295(00)00845-1
Burkman RT (2004) Chronic pelvic pain of bladder origin: epidemiology, pathogenesis and quality of life. J Reprod Med 49:225–229.
Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG (2009) Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int 103:910–918. https://doi.org/10.1111/j.1464-410X.2008.08162.x
Parkin J, Shea C, Sant GR (1997) Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis – a practical approach. Urology 49: 105–107. https://doi.org/10.1016/S0090-4295(97)00181-7
Fall M, Oberpenning F, Peeker R (2008) Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? Eur Urol 54:65–75. https://doi.org/10.1016/j.eururo.2008.03.086
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
Morales A, Emerson L, Nickel J, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156:445–448. https://doi.org/10.1016/S0022-5347(01)65933-0
Riedl C, Engelhardt P, Daha K, Moraskis N, Pfluger H (2008) Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J 19:717–721. https://doi.org/10.1007/s00192-007-0515-5
Daha LK, Lazar D, Simak R, Pfluger H (2008) The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with BPS/IC: preliminary results. Int Urogynecol J 19: 987–990. https://doi.org/10.1007/s00192-008-0560-8
Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Erlbaum, Hillsdale.
Lv YS, Zhou HL, Mao HP, Gao R, Wang YD, Xue XY (2012) Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int Urogynecol J 23:1715–1720. https://doi.org/10.1007/s00192-012-1802-3
Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of Intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47:393–397. https://doi.org/10.1016/j.eururo.2004.10.022
Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ESC (2012) Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int. Urogynecol J 23:1533–1539. https://doi.org/10.1007/s00192-012-1699-x
Gafni-Kane A, Botros SM, Du H (2013) Measuring the success of combined intravesical dimethylsulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J 24:303–311. https://doi.org/10.1007/s00192-012-1832-x
Cervigni M, Natale F, Nasta L, Padoa A, Lo Voi R, Porru D (2008) A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J 19:943–947. https://doi.org/10.1007/s00192-008-0572-4
Porru D, Cervigni M, Nasta L, Natale F, Lo Voi R, Tinelli C et al (2008) Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome. Rev Recent Clin Trials 3:126–129. https://doi.org/10.2174/157488708784223817
Gauruder-Burmester A,Wildt B, Tunn R (2006) Treatment of overactive bladder with sodium chondroitin sulphate. Zentralbl Gynakol 128:336–340. https://doi.org/10.1055/s-2006-933378
Gauruder-Burmester A, Popken G (2009) Follow-up at 24 months after treatment of overactive bladder with 0.2% sodium chondroitin sulfate. Aktuelle Urol 40:355–359. https://doi.org/10.1055/s-0029-1224600
Hazewinkel MH, Stalpers LJA, Dijkgraaf MG, Roovers JWR (2011) Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. Int Urogynecol J 22:725–730. https://doi.org/10.1007/s00192-010-1357-0
Parsons CL (2005) Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 65:45–48. https://doi.org/10.1016/j.urology.2004.08.056
Parsons CL, Zupkas P, Proctor J, Koziol J, Franklin A, Giesing D et al (2012) Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med 9:207–212. https://doi.org/10.1111/j.1743-6109.2011.02542.x
Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa R, Usai E (1997) Results of treatment of refractory interstitial cystitis within travesical hyaluronic acid. Urol Int 59:26–29. https://doi.org/10.1159/000283012
Figuereido AB, Palma P, Riccetto C, Hermann V, Dambros M, Capmartin R (2011) Clinical and urodynamic experience with intravesical hyaluronic acid in painful bladder syndrome associated with interstitial cystitis. Actas Urol Esp 35:184–187. https://doi.org/10.1016/j.acuro.2010.09.004
Cervigni M, Natale F, Nasta L, Mako A (2012) Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: longterm treatment results. Int Urogynecol J 23:1187–1192. https://doi.org/10.1007/s00192-012-1742-y
Sorensen RB (1996) Chondroitin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol 2:16–18. https://doi.org/10.1016/S1569-9056(03)00036-8
Shao Y, Shen ZJ, Rui WB, Zhou WL (2010) Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology 75:547–550. https://doi.org/10.1016/j.urology.2009.09.078
Nickel JC, Egerdie B, Steinhoff G, Palmer B, Hanno P (2010) A multicenter, randomized, double-blind, and parallel groups: pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with IC/PBS.Urology 76:804–809. https://doi.org/10.1016/j.urology.2010.03.016
Nickel JC, Hanno P, Kumar K, Thomas H (2012) Effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 79:1220–1224. https://doi.org/10.1016/j.urology.2012.01.059
Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJA (1997) A placebo-controlled study of intravesical pentosane polysulphate for the treatment of interstitial cystitis. Br J Urol 79:168–171. https://doi.org/10.1046/j.1464-410X.1997.03384.x
Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ (2008) Safety and efficacy of the use of intravesical and oral pentosane polysulfate sodium for interstitial cystitis: a randomized doubleblind clinical trial. J Urol 179:177–185. https://doi.org/10.1016/j.juro.2007.08.170
Sairanen J, Leppilahti M, Tammela TLJ, Paananen I, Aaltomaa S, Taari K, Ruutu M (2009) Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on interstitial cystitis? Scand J Urol Nephrol 43:212–219. https://doi.org/10.1080/00365590802671031
Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR (2011) Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 22: 401–405. https://doi.org/10.1007/s00192-010-1294-y
Lai MC, Kuo YC, Kuo HC (2013) Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome. A comparative randomized assessment of different regimens. Int J Urol 20:203–207. https://doi.org/10.1111/j.1442-2042.2012.03135.x
Kallestrup E, Jorgensen S, Nordling J, Hald H (2005) Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147. https://doi.org/10.1080/00365590410015876-1
Gupta SK, Pidcock L, Parr NJ (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 96:1063–1066. https://doi.org/10.1111/j.1464-410X.2005.05776.x
Steinhoff G (2003) The efficacy of chondroitin sulphate in treating interstitial cystitis. Eur Urol Suppl 2:14–16. https://doi.org/10.1016/S1569-9056(03)00035-6
Nordling J, van Ophoven A (2008) Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung 58:328–335.
Nickel J, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K (2008) A real-life multicenter clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int 103:56–60. https://doi.org/10.1111/j.1464-410X.2008.08028.x
Porru D, Leva F, Parmigiani A, Barletta D, Choussos D, Gardella B et al (2011) Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J 23:1193–1199. https://doi.org/10.1007/s00192-011-1546-5
Bade JJ, Mensink HJ, Laseur M (1995) Intravesical treatment of interstitial cystitis with a heparin analogue. Br J Urol 75:260. https://doi.org/10.1111/j.1464-410X.1995.tb07332.x
Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, Wyndaele JJ (2012) Contemporary management of the painful bladder: a systematic review. Eur Urol 61:29–53. https://doi.org/10.1016/j.eururo.2011.07.069
Matsuoka PK, Hadda JM, Pacetta AM, Baracat EC (2012) Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J 23:1147–1153. https://doi.org/10.1007/s00192-012-1686-2